Julio Chavez, MD, Moffitt Cancer Center

Articles by Julio Chavez, MD, Moffitt Cancer Center

Treatment of R/R DLBCL: Beyond CAR T Therapy

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Phase 2B SADAL Trial in R/R DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

RE-MIND Study in R/R DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

L-MIND Study in R/R DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Standard of Care for Relapsed/Refractory DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Novel Therapies: R2-GDP-GOTEL and Smart Start

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Novel Treatment Combinations for R/R DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Relapsed/Refractory DLBCL: Unmet Needs

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Emerging Treatments for Relapsed/Refractory DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

SADAL Trial Regimen FDA Approval

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

SADAL Trial Overview

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

CAR T-Cell Therapy Clinical Trials

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

CAR T-Cell Therapy Response Rates

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

CAR T Cell Therapy in Relapsed/Refractory DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Relapsed/Refractory DLBCL Treatment Landscape

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

R/R DLBCL: Transplant Eligibility and R-CHOP

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Newly Diagnosed DLBCL: Treatment Decision Factors

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

DLBCL Risk Assessment and Genetic Signatures

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Therapy Initiation Prior to Cytogenetic Testing Results

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Latest Updated Articles

SADAL Trial Overview
July 17th 2020
CAR T-Cell Therapy Clinical Trials
July 17th 2020
DLBCL Risk Assessment and Genetic Signatures
July 17th 2020
CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL
September 22nd 2020
Therapy Initiation Prior to Cytogenetic Testing Results
July 17th 2020
$CAR T Cell Therapy in Relapsed/Refractory DLBCL$
CAR T Cell Therapy in Relapsed/Refractory DLBCL
July 17th 2020

Julio Chavez, MD, Moffitt Cancer Center

Articles by Julio Chavez, MD, Moffitt Cancer Center

Treatment of R/R DLBCL: Beyond CAR T Therapy

Phase 2B SADAL Trial in R/R DLBCL

RE-MIND Study in R/R DLBCL

L-MIND Study in R/R DLBCL

CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL

Standard of Care for Relapsed/Refractory DLBCL

Novel Therapies: R2-GDP-GOTEL and Smart Start

Novel Treatment Combinations for R/R DLBCL

Relapsed/Refractory DLBCL: Unmet Needs

Emerging Treatments for Relapsed/Refractory DLBCL

SADAL Trial Regimen FDA Approval

SADAL Trial Overview

CAR T-Cell Therapy Clinical Trials

CAR T-Cell Therapy Response Rates

CAR T Cell Therapy in Relapsed/Refractory DLBCL

Relapsed/Refractory DLBCL Treatment Landscape

R/R DLBCL: Transplant Eligibility and R-CHOP

Newly Diagnosed DLBCL: Treatment Decision Factors

DLBCL Risk Assessment and Genetic Signatures

Therapy Initiation Prior to Cytogenetic Testing Results

Latest Updated Articles

Trending on OncLive

Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma

Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer

Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia

AI Finds New Applications in Oncologic Surgery, Drug and Biomarker Screening, and Clinical Trial Design

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD